RNA, U6 small nuclear 967, pseudogeneGenealiases: []
Q-omics provides the consensus-scored RNU6-967P profile across patient tissues and cancer cell-line models. RNU6-967P expression is associated with patient survival in 9 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RNU6-967P is differentially expressed in 4, with the highest sampling consensus in LUSC. Additionally, RNU6-967P RNA expression shows 12,234 significant gene co-expression associations, with the highest sampling consensus in UCEC. Together, these results highlight ACC, LUSC, and UCEC as cancer lineages where RNU6-967P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU6-967P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU6-967P survival associations across molecular data types. RNU6-967P RNA expression shows survival associations in the most cancer types (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU6-967P RNA expression–survival associations across cancer types. High RNU6-967P expression shows unfavorable associations in ACC, UCEC, KIRC, STAD, HNSC and UVM. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RNU6-967P RNA expression.
This table summarizes RNU6-967P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for RNU6-967P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU6-967P shows lower tumor expression in LUSC, LUAD, THCA and KIRC. The LUSC box plot shows higher RNU6-967P RNA expression in normal versus tumor tissue (log2 FC = −1.751, t-test p < 0.001).
This table shows molecular features associated with RNU6-967P in patient tissues and cancer cell lines. In patient samples, RNU6-967P shows the broadest associations at the RNA and protein expression levels, with UCEC recurring as the lineage with the largest associated feature set.
